Advanced Accelerator Applications Reports 29.6% Sales

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Advanced Accelerator Applications Reports 29.6% Sales Growth in the First Quarter of 2016

First Quarter Highlights:

  • Sales for the first quarter of 2016 increased 29.6% compared to the first quarter of 2015
  • Purchased 100% of the IDB Group to strengthen AAA’s commercial positioning of Lutathera
  • Entered into a non-exclusive agreement with Zevacor for the preparation and delivery of Somakit-TATE in the US
  • Signed an exclusive licensing agreement with Johns Hopkins University to develop and market PSMA receptor ligand in prostate cancer for clinical therapeutic and diagnostic purposes        

              SAINT-GENIS-POUILLY, France, May 31, 2016 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ: AAAP ) (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (MNM), today announced its financial results for the first quarter of 2016.

Mr. Stefano Buono, AAA’s CEO, commented, “Our continued sales momentum provides a strong foundation for the commercial launches of both Somakit and Lutathera, as well as the expansion of our theragnostic franchise as a whole.”  Mr. Buono continued, “We are committed to continuing to deliver improved outcomes for patients with unmet medical needs through our specialized expertise in the development and production of molecular nuclear medicines, and the accomplishments of this past quarter underscore the progress we are making to that end.”

First Quarter 2016 Financial Results

Total sales for the first quarter of 2016 were €26.92 million (USD (1) 30.65 million), a 29.6% year-on-year increase compared to €20.76 million (USD (1) 23.64 million) in the prior year period.

Operating loss for the first quarter of 2016 was €1.12 million (USD (1) 1.28 million), compared to a loss of €1.58 million (USD (1) 1.80 million) for the prior year period.

For the first quarter of 2016, the Company reported a net loss of €2.98 million (USD (1) 3.39 million), compared to €5.90 million (USD (1) 6.72 million) for the prior year period.

For the first quarter of 2016, adjusted EBITDA (see corresponding reconciliation exhibit below) was €2.08 million (USD (1) 2.37 million), a 88.83% year-on-year increase compared to €1.10 million (USD (1) 1.25 million) for the prior year period.

(1) Translated solely for convenience into USD at the noon buying rate of  € 1.00=US$1.1386 at March 31, 2016.

Lutathera and Somakit Update

In January 2016, AAA announced the signing of an exclusive license agreement with Johns Hopkins University to develop PSMA receptor ligand in prostate cancer. This agreement enables AAA to broaden its pipeline with PSMA, which could be used to treat, image, monitor and stage prostate cancer, utilizing a clinical development strategy similar to Lutathera and Somakit.

Additional Lutathera NETTER-1 Phase III data were presented both on January 22, 2016 at the 2016 Gastrointestinal Cancer Symposium (ASCO GI) in San Francisco, California and on March 11, 2016 at the 13th Annual European Neuroendocrine Tumor Society (ENETS) conference in Barcelona, Spain.

Also in January 2016 AAA entered into a non-exclusive agreement with Zevacor for the preparation and delivery of Somakit-TATE in the US.

The FDA extended the Prescription Drug User Fee Act (PDUFA) date for its Priority Review of the NDA for Somakit-TATE, AAA’s investigational kit for neuroendocrine tumor diagnosis and follow-up. The PDUFA date has been extended to June 1, 2016.

About Lutathera and NETTER-1

Lutathera (or 177 Lu-DOTATATE) is a Lu-177-labeled somatostatin analogue peptide currently under development for the treatment of gastro entero pancreatic neuroendocrine tumors (GEP-NETs). This novel compound has received orphan drug designation from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Lutathera was also granted fast-track designation by the FDA in April 2015 for the treatment of inoperable progressive midgut NETs. The FDA provides fast-track designation to product candidates that treat serious conditions and fill an unmet medical need in order to facilitate their development and expedite their review. Lutathera is also currently administered on a compassionate use and named patient basis for the treatment of NETs in ten European countries and in the US under an Expanded Access Program (EAP).

Lutathera belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (“PRRT“), which involves targeting carcinoid tumors with radiolabeled somatostatin analogue peptides. Currently at the end of its Phase III development in its pivotal NETTER-1 study, Lutathera is the most advanced candidate in development for PRRT.

Lutathera’s NETTER-1 study is the first Phase 3 international, multi-center, randomized, controlled trial evaluating 177Lu-DOTA0-Tyr3-Octreotate (Lutathera) in patients with inoperable, progressive, somatostatin receptor positive midgut NETs. 230 patients with Grade 1-2 metastatic midgut NETs (both functioning and not functioning) were randomized to receive Lutathera 7.4 GBq every 8 weeks (x4 administrations) versus Octreotide LAR 60 mg every 4-weeks. The primary endpoint was PFS per RECIST 1.1 criteria, with objective tumor assessment performed by an independent reading center every 12 weeks. Secondary objectives included objective response rate, overall survival, safety, and health-related quality of life.

The Phase 3 NETTER-1 study met its primary endpoint by demonstrating that treatment with Lutathera was associated with a statistically significant and clinically meaningful risk reduction of 79% in disease progression or death versus a treatment with a double dose of Octreotide LAR  (hazard ratio 0.21, 95% CI: 0.13-0.33; p<0.0001). The median PFS in the Lutathera arm is not yet reached, whilst the median PFS in the Octreotide LAR 60 mg arm was 8.4 months.

Complete and partial responses (CR+PR) were reported in 18 patients (18%) in the Lutathera group versus 3 (3%) in the Octreotide LAR 60 mg group (p=0.0008). Although the overall survival (OS) data is not mature enough for a definitive analysis, the number of deaths was 14 in the Lutathera group and 26 in the Octreotide LAR 60 mg group  (p=0.0043 at interim analysis), which suggests an improvement in OS. Only 5% of the patients (6 patients) experienced Lutathera dose modifying toxicity. Adverse events grade 3 or 4 neutropenia, thrombocytopenia and lymphopenia occurred in 1%, 2% and 9% of the patients in Lutathera arm vs. none in the control group.

The Phase 3 NETTER-1 study provides evidence of a clinically meaningful and statistically significant increase in PFS and objective response rate (”ORR”), and also suggests a survival benefit in patients with advanced midgut neuroendocrine tumors treated with Lutathera.

The adverse events observed for Lutathera in the NETTER-1 study were consistent with the results of Lutathera’s previous Phase I-II study, with Lutathera demonstrating a favorable safety profile.

About Advanced Accelerator Applications

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicine (MNM) products. AAA’s lead therapeutic product candidate, Lutathera, is a novel MNM compound that AAA is currently developing for the treatment of Neuro Endocrine Tumors, a significant unmet medical need. Founded in 2002, AAA has its headquarters in Saint-Genis-Pouilly, France. AAA currently has 18 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 440 employees in 13 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, The Netherlands, Belgium, Israel, U.S. and Canada). AAA is listed on the Nasdaq Global Select Market under the ticker “AAAP”. For more information please visit: www.adacap.com

About Molecular Nuclear Medicine (“MNM”)

Molecular Nuclear Medicine is a medical specialty using trace amounts of active substances, called radiopharmaceuticals, to create images of organs and lesions and to treat various diseases, like cancer. The technique works by injecting targeted radiopharmaceuticals into the patient’s body that accumulate in the organs or lesions and reveal specific biochemical processes. Molecular Nuclear Diagnostics employs a variety of imaging devices and radiopharmaceuticals. PET (Positron Emission Tomography) and SPECT (Single Photon Emission Tomography) are highly sensitive imaging technologies that enable physicians to diagnose different types of cancer, cardiovascular diseases, neurological disorders and other diseases in their early stages.

Reconciliation of adjusted EBITDA to net loss for the year from continuing operations for the three months ended March 31, 2016

                       
  In USD thousands   Three months ended in EURO thousands
    03.31.2016     03.31.2016     03.31.2015
Net loss for the period from continuing operations   (3,388 )     (2,976 )     (5,903 )
Adjustments:                      
Finance income (including changes in fair value of contingent consideration)   (1,484 )     (1,303 )     (14 )
Finance costs (including changes in fair value of contingent consideration)   3,963       3,481       3,801  
Income taxes   (367 )     (322 )     535  
Depreciation and amortization   3,642       3,199       2,682  
Adjusted EBITDA   2,367       2,079       1,101  
Sales   30,650       26,919       20,764  
Adjusted EBITDA margin   7.72 %     7.72 %     5.30 %
                       

(1)   Translated solely for convenience into dollars at the noon buying rate of  €1.00=US$1.1386 at March 31, 2016.

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain forward-looking statements. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the timing of our submission of applications for regulatory approvals, EMA, FDA and other regulatory approvals for our product candidates, the occurrence of side effects or serious adverse events caused by or associated with our products and product candidates; our ability to procure adequate quantities of necessary supplies and raw materials for Lutathera and other chemical compounds acceptable for use in our manufacturing processes from our suppliers; our ability to organize timely and safe delivery of our products or product candidates by third parties; any problems with the manufacture, quality or performance of our products or product candidates; the rate and degree of market acceptance and the clinical utility of Lutathera and our other products or product candidates; our estimates regarding the market opportunity for Lutathera, our other product candidates and our existing products; our anticipation that we will generate higher sales as we diversify our products; our ability to implement our growth strategy including expansion in the U.S.; our ability to sustain and create additional sales, marketing and distribution capabilities; our intellectual property and licensing position; legislation or regulation in countries where we sell our products that affect product pricing, taxation, reimbursement, access or distribution channels; and general economic, political, demographic and business conditions in Europe, the U.S. and elsewhere. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME Three Months ended March 31, 2016 and 2015

In € thousands     03.31.2016     03.31.2015  
       
Sales     26,919     20,764  
Raw materials and consumables used     (5,624 )   (4,252 )
Personnel costs     (9,679 )   (6,158 )
Other operating expenses     (10,847 )   (10,613 )
Other operating income     1,310     1,360  
Depreciation and amortization     (3,199 )   (2,682 )
       
Operating loss     (1,120 )     (1,581 )
       
       
Finance income (including changes in fair value of contingent consideration)     1,303     14  
               
Finance costs (including changes in fair value of contingent consideration)     (3,481 )   (3,801 )
       
Net finance loss     (2,178 )     (3,787 )
       
       
Loss before income taxes     (3,298 )     (5,368 )
       
Income taxes     322       (535 )
       
Loss for the period     (2,976 )     (5,903 )
       
       
Attributable to:      
Owners of the Company     (2,976 )   (5,903 )
Non-controlling interests     -     -  
       
Loss per share      
       
Basic (€ per share)     (0.04 )   (0.09 )
Diluted (€ per share)     (0.04 )   (0.09 )
       
       

Condensed Consolidated statements of comprehensive income Three Months ended March 31, 2016 and 2015

In € thousands     03.31.2016     03.31.2015  
Loss for the period     (2,976 )     (5,903 )
       
Other comprehensive income / (expense):      
       
Items that may be reclassified subsequently to profit or loss      
Exchange differences on translating foreign operations     (761 )   3,860  
       
Items that will never be reclassified subsequently to profit or loss      
Remeasurement of defined benefit liability     (37 )   (19 )
       
Other comprehensive income /(expense) net of tax (1)     (798 )   3,841  
Total comprehensive loss for the period     (3,774 )     (2,062 )
       
Total comprehensive loss attributable to:      
Owner of the Company     (3,774 )   (2,062 )
Non-controlling interests     -     -  
               

(1) Tax effect of €16 thousand at March 31, 2016 and €9 thousand at March 31, 2015.

Condensed Consolidated statements of financial position at March 31, 2016

ASSETS (In € thousands)     03.31.2016     12.31.2015  
Non-current assets     145,329       116,872  
Goodwill     33,215     22,662  
Other intangible assets     44,703     31,884  
Property, plant and equipment     61,094     56,332  
Financial assets     961     1,512  
Other non-current assets     5,105     4,185  
Deferred tax assets     251     297  
Current assets     134,109     157,231  
Inventories     5,179     4,105  
Trade and other receivables     27,830     23,625  
Other current assets     12,646     10,615  
Cash and cash equivalents     88,454     118,886  
TOTAL ASSETS     279,438       274,103  
       
EQUITY AND LIABILITIES (In € thousands)     03.31.2016     12.31.2015  
Equity attributable to owners of the Company     167,284       169,754  
Share capital     7,856     7,856  
Share premium     213,982     213,982  
Reserves and retained earnings     (51,578 )   (35,083 )
Net loss for the period / year     (2,976 )   (17,001 )
Total equity     167,284       169,754  
Non-current liabilities     70,516       68,341  
Non-current provisions     10,334     9,968  
Non-current financial liabilities     15,197     16,205  
Deferred tax liabilities     5,774     2,804  
Other non-current liabilities     39,211     39,364  
Current liabilities     41,638       36,008  
Current financial liabilities     5,204     5,560  
Trade and other payables     16,916     14,710  
Other current liabilities     19,518     15,738  
Total liabilities     112,154       104,349  
TOTAL EQUITY AND LIABILITIES     279,438       274,103  
               
               

Condensed Consolidated statements of cash flows Three Months ended March 31, 2016 and 2015

In € thousands   03.31.2016     03.31.2015  
     
Cash flows from operating activities    
Net loss for the period   (2,976 )   (5,903 )
Adjustments:    
Depreciation, amortization and impairment of non-current assets   3,199     2,682  
Share based payment expense   1,306     395  
Loss / (Gain) on disposal of property, plant and equipment   72     1  
Financial result   2,178     3,787  
Income tax expense   (322 )   535  
Subtotal   3,457       1,497  
     
Increase in inventories   (584 )   (337 )
Increase in trade receivables   (3,300 )   (4,201 )
Increase / (decrease) in trade payables   1,572     (127 )
Change in other receivables and payables   (3,524 )   474  
Increase / (decrease) in provisions   81     (19 )
Change in working capital   (5,755 )     (4,210 )
     
Income tax paid   (425 )   (223 )
Net cash used in operating activities   (2, 723 )     (2,936 )
Cash flows from investing activities    
Acquisition of property, plant and equipment   (3,623 )   (1,590 )
Acquisition of intangible assets   (577 )   (450 )
Acquisition of financial assets   (221 )   (220 )
Reimbursment of financial asset   760     -  
Interests received   130     -  
Proceeds from disposal of property, plant and equipment   -     31  
Acquisition of subsidiaries, net of cash acquired   (19,959 )   -  
Net cash used in investing activities   (23,490 )     (2,229 )
Net cash from financing activities    
Payment of deferred and contingent liabilities to former owners of acquired subsidiaries   (194 )   -  
Repayment of borrowings   (1,283 )   (1,250 )
Interests paid   (95 )   (202 )
Net cash used in  financing activities   (1,572 )     (1,452 )
     
Net decrease in cash and cash equivalents   (27,785 )     (6,617 )
     
Cash and cash equivalents at the beginning of the period   118,886     45,096  
Effect of exchange rate changes on cash and cash equivalents   (2,647 )   646  
Cash and cash equivalents at the end of the period   88,454       39,125  

Contacts AAA Investor Relations Jordan Silverstein Director of Investor Relations jordan.silverstein@adacap.com Tel: + 1-212-235-2394 Media enquiries FTI Consulting Kimberly Ha Kimberly.Ha@fticonsulting.com Tel: +1-212-850-5612 Axess Public Relations (Italy) Dario Francolino dario.francolino@axesspr.com Tel: +39 3488818029

Scroll down for more posts ▼

Top 10 Most Recent News Articles

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 124

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 7

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 415

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 324

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 136

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 77

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 42

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 44

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 258

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

VOOG's 15-Year Climb: Compounding Gains or Just a Mirage?

Updated Category News Views 255

Fifteen years back, you could have dropped $1000 into the Vanguard S&P 500 Growth ETF (NYSE:VOOG), and that cash would’ve exploded into a whopping $7,164.65 today. That’s a staggering annualized return of 14.01%, comfortably outpacing the market by about 2.35%. Sounds easy, right? But let’s peel back this seemingly golden curtain. VOOG's Performance: The Big Picture...

Continue Reading
Mercer International Inc. Faces Financial Challenges in Q2 2025

Updated Category News Views 256

Financial Overview of Mercer International Inc. for Q2 2025 Mercer International Inc. recently disclosed its financial performance for the second quarter of 2025, revealing significant challenges. The company reported an Operating EBITDA of negative $20.9 million alongside a net loss of $86.1 million, a stark contrast to the positive $30.4 million Operating EBITDA and a...

Continue Reading
EU's Strategic Response to Potential Trade Challenges with Trump

Updated Category News Views 167

EU's Trade Engagement Strategy with the New Administration The European Union is gearing up for an essential phase in its trade relations with the U.S. as Donald Trump prepares to take office once again. The EU's ministers have clearly expressed the need to foster constructive dialogue regarding trade policies while remaining vigilant about any potential tariff...

Continue Reading
Regenative Labs Casts Spotlight on Plantar Fascia Innovations

Updated Category News Views 44

Rethinking Plantar Fasciitis with Wharton’s Jelly When it comes to those of us keeping an eye on regenerative medicine, it’s like standing on the edge of a wild frontier sometimes. Today, we’ve got Regenative Labs out of Pensacola shining a light on something that’s often a real pain—literally and figuratively: plantar fasciitis. Clinical Studies with Promising...

Continue Reading
GC Biopharma's BARYCELA Secures Marketing Authorization

Updated Category News Views 171

GC Biopharma's Breakthrough with BARYCELA GC Biopharma, a prominent South Korean pharmaceutical company, has achieved a significant milestone with the recent marketing authorization of its varicella vaccine, BARYCELA, in Vietnam. This accomplishment follows earlier domestic approval and WHO Pre-Qualification, demonstrating the company’s commitment to expanding its...

Continue Reading